CRISPR slows the growth of triple-negative breast cancer in mice

A team of researchers at Boston Children's Hospital has developed an innovative way to knock out the oncogene Lipocalin 2 using the editing system CRISPR and has shown its potential for treating triple-negative breast tumors in mice.